A study to evaluate the effect of fluvoxamine, paroxetine, and smoking on a single IPN60170 (mesdopetam) dose in healthy male participants

This study will investigate the pharmacokinetics (PK), safety, and tolerability of IPN60170 and its metabolites in smokers and nonsmokers healthy male participants. IPN60170 is being developed as a potential treatment to reduce levodopa-induced dyskinesia (LID) and psychosis in patients with Parkinson’s Disease (PD).

En rapport Clinical Trials